Cefpirome


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : IV 1-2 g 12 hrly.
Dosage Details
Intravenous
Susceptible infections
Adult: As sulfate: 1-2 g every 12 hr via IV inj over 3-5 minutes or infuse over 20-30 minutes.
Renal Impairment
Loading dose: 1-2 g followed by a maintenance dose adjusted according to CrCl.
CrClDosage
<5 (in haemodialysis patients)0.5 or 1 g once daily with half-dose after each dialysis session.
20-500.5-1 g bid.
5-200.5-1 g once daily.
Contraindications
Hypersensitivity; porphyria.
Special Precautions
Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation.
Adverse Reactions
Rash, pruritus, urticaria; nausea, vomiting, abdominal pain, diarrhoea; increased plasma levels of ASAT, ALAT, gamma-GT, LDH, bilirubin and/or alkaline phosphatase; interstitial nephritis, acute renal failure; thrombocytopaenia, eosinophilia, haemolytic anaemia, neutropaenia, agranulocytosis; thrombophloebitis, pain at Inj site; convulsions, fever; haemorrhage.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Reduced clearance with probenecid.
Lab Interference
Interferes with Jaffe method of creatinine conc measurement in determining renal function.
Action
Description: Cefpirome binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Distribution: Widely distributed into body tissues and fluids; enters breast milk. Protein-binding: 10%
Excretion: Mainly by the kidneys via the urine (80-90% as unchanged); significantly removed by haemodialysis; 2 hrs (elimination half-life); prolonged in renal impairment.
Storage
Store below 25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefpirome from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Zeferom
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in